Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ... navigate and understand both the current standard of care ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... whether technology developed to win races on the Formula ... obesity.  This unique healthcare collaboration between McLaren Applied Technologies ... academics at University Campus Suffolk is being funded by ... inspired by equipment used to collect data about the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS ... enhancement to its Online Web Portal for Life Science ... have the ability to specify the subject matter of ... 50 life science sub-domains. This will help reduce time-to-delivery ... scientific fields, and decrease the likelihood of error. , ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... ) in the Russian Federation ... members of the Commonwealth Independent States (CIS). Nemonoxacin is ... infections including those caused by drug-resistant bacteria. Under ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Minimally Invasive Treatment of Bone Fractures Achieves Significant ... Feb. 23 IlluminOss Medical Inc., a medical ... Stabilization System for orthopedic surgery, today announced that ... Registration issued by BSI (British Standards Institute). ...
... February 23 Health Robotics and Can-Med,today ... agreement whereby Can-Med,has acquired the exclusive distribution ... Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, Turkmenistan, Kyrgyzstan, ... only automated, point-of-care-distributed, and fail-safe,robotic system for ...
... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
Cached Biology Technology:IlluminOss Medical Receives ISO 13485 Certification 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3
(Date:4/15/2014)... LIVERMORE, Calif. Zero-emission hydrogen fuel cell systems soon could ... industrial settings at lower costs and with faster refueling ... Sandia National Laboratories and Hawaii Hydrogen Carriers (HHC). , ... solid-state hydrogen storage system that can refuel at low ... to charge a battery-powered forklift, giving hydrogen a competitive ...
(Date:4/15/2014)... research published in the March/April 2014 issue of ... shows whey protein, either as a supplement combined ... or weight-maintenance diet, may provide men and women benefits ... 14 randomized controlled trials with a total of 626 ... that used whey protein to replace calories in the ...
(Date:4/14/2014)... you,re over 24 years of age you,ve already reached ... according to a new Simon Fraser University study. ... professor Mark Blair, Thompson,s thesis supervisor, and Andrew Henrey, ... news in a just-published PLOS ONE Journal ... science experiments to rest on big data, the trio ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Study says we're over the hill at 24 2
... cells are the body,s mechanics, repairing damaged tissues and organs. ... of cell in the body, scientists believe they hold the ... scientists from the University of Victoria have found a new ... for regenerative medicine. "Cells in your body grow and ...
... Md. (March 1, 2012)The American Physiology Society (APS) has announced ... experimental animals and the sex or gender of humans used ... 13 peer-reviewed journals. This notable requirement for all research study ... be presented in an editorial, " In Pursuit of Scientific ...
... PULLMAN, Wash.A Washington State University researcher has demonstrated that a ... just an exposed animal but the next three generations of ... the compounds change the way genes turn on and offthe ... Skinner and expanded on in the current issue of the ...
Cached Biology News:APS issues new policy requiring identification of sex or gender in reporting scientific research 2APS issues new policy requiring identification of sex or gender in reporting scientific research 3Effects of environmental toxicants reach down through generations 2
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Human Complement Component C5a MAb (Clone 295003)...
Human Serpin A8/AGT Affinity Purified Polyclonal Ab Keywords: Ang II, AngII, Hypertension, Salt Homeostasis, Pre-eclampsia...
Mouse Axl MAb (Clone 175128)...
Biology Products: